Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

25th May 2020 – Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)

Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2  clinical study of TLX101 (also known as ¹³¹I-IPA or 4-L-[¹³¹I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).

The IPAX-1 poster will present an overview of the study, which is evaluating the safety, dosing schedule and preliminary efficacy of TLX101 in combination with external radiation therapy as a novel treatment approach for patients with recurrent GBM.

“We are grateful to the investigators, site staff, patients and their families and carers who are involved in the IPAX-1 study,” said Dr. Rosalind Wilson, Global Head of Drug Development, Telix Pharmaceuticals. “Telix is committed to researching the potential of molecularly-targeted radiation to address the important unmet medical need of patients who suffer from this terrible disease.”

Details of the presentation are as follows:

Title: IPAX-1: Phase I/II study of ¹³¹I-iodo-phenylalanine combined with external radiation therapy as treatment for patients with glioblastoma multiforme

Abstract Number:        TPS2578

Poster Number:            69

Presenting Author:      Josef Pichler, MD

Session:                           Central Nervous System Tumors

The poster will be available on demand by accessing the ASCO Meeting Library beginning Friday, May 29 at 8:00 am EDT.